The spectacular rise and even more dramatic fall of Yaojie Ankan, a pharmaceutical heavyweight on the Hong Kong Stock Exchange, serves as a sobering reminder of the volatility inherent in high-growth biotech valuations. In just 270 days, the company’s market capitalization has withered from a peak of nearly 270 billion HKD to a mere 4.6 billion HKD. On June 23, the stock plunged by nearly 60% in a single trading session, marking a brutal 'kneecap' correction for investors who once cheered its 50-fold surge post-IPO.
The immediate catalyst for this freefall was the expiration of a critical six-month lock-up period on June 22. Under HKEX listing rules, the majority of the company’s shares—approximately 382 million shares representing over 90% of the total share capital—became eligible for sale by controlling shareholders. This massive injection of potential liquidity into a sensitive market triggered a preemptive sell-off as traders raced to exit before the anticipated flood of insider selling materialized.
Beyond the technical pressure of the lock-up expiry, Yaojie Ankan’s aggressive capital-raising strategy has soured investor sentiment. Within less than a year of its June 2025 listing, the company has executed three separate H-share placements to raise a total of 624 million HKD. These frequent, discounted fundraising rounds have significantly diluted existing shareholders and signaled a desperate need for cash, undermining confidence in the firm’s long-term financial health.
Market analysts note that the crash was not necessarily driven by a single large-scale liquidation but by a shift in market psychology. When the prospect of massive share dilution meets a period of low liquidity and heightened risk aversion, valuations are often 'beaten back to their original form.' For Yaojie Ankan, the lack of a strong fundamental floor meant that once the speculative fever broke, there was little to prevent a total collapse in share price.